Current Edition

Upcoming Events

Advertisement

Volume 5 Issue 3

ADCs – From Lab to Clinical Development

Antibody-drug conjugates (ADCs) are a family of targeted therapeutic agents for the treatment of cancer. Compared to traditional small-molecule approaches, ADCs offer...
Continue Reading →
news

Early tests suggest Vir, GSK antibody could hold up versus omicron

Omicron's detection last week triggered travel restrictions and renewed public health measures around the world as scientists and government officials warned the vari...
Continue Reading →
news

Regeneron warns its antibody drug may be less potent versus omicron

Regeneron's drug is the top-selling COVID-19 treatment in the U.S., one of three antibody drugs currently authorized by the Food and Drug Administration for people wh...
Continue Reading →
news

Sphere Fluidics closes a $40 million funding round led by Sofinnova Partners and Redmile Group

Cambridge, UK, 28 October 2021: Sphere Fluidics, a company that has developed and is commercialising single cell analysis systems underpinned by its proprietary picod...
Continue Reading →
news

US stocks up on COVID-19 antibody drugs amid shortage concerns

The antibody treatments from Regeneron and Eli Lilly have been proven effective in reducing the risk of hospitalization or death from COVID-19 in certain high-risk in...
Continue Reading →
news

AACR 2018: GamaMabs Pharma to present new data on expression of Anti-Müllerian Hormone type II Receptor in non-gynecological cancers and on first ADC candidate targeting AMHRII

AMHRII expression and Antibody-Drug Conjugate preclinical data suggest potential broader applications for anti-AMHRII-based therapy GamaMabs Pharma, a biotechnolog...
Continue Reading →